A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme.

摘要: Abstract Background Seasonal influenza imposes a significant health and economic burden in South Africa, particularly populations vulnerable to severe consequences of influenza. This study assesses the cost-effectiveness Africa’s seasonal vaccination strategy, which involves vaccinating with trivalent inactivated vaccine (TIV) during routine facility visits. Vulnerable included our analysis are persons aged ≥ 65 years; pregnant women; living HIV/AIDS (PLWHA), any age underlying medical conditions (UMC) children aged 6–59 months. Method We employed World Health Organisation’s (WHO) Cost Effectiveness Tool for Influenza Vaccination (CETSIV), decision tree model, evaluate 2018 campaign from public healthcare provider societal perspective. CETSIV was populated existing country-specific demographic, epidemiologic coverage data estimate incremental ratios (ICERs) by comparing costs benefits programme no vaccination. Results The highest number clinical events (influenza cases, outpatient visits, hospitalisation deaths) were averted PLWHA other UMCs. Using threshold US$ 3 400 per quality-adjusted life year (QALY), findings suggest that is cost-effective all except ICERs ranged from ~US$ 1 750 /QALY to ~US$ 7 500/QALY children. In probabilistic sensitivity analyses, women, PLWHA, UMCs aged ≥65 years in >80% simulations. These robust changes many model inputs but most sensitive uncertainty estimates influenza-associated illness burden. Conclusion Africa's strategy opportunistically targeting visits cost-effective. A budget impact will be useful supporting future expansions programme.